MA44659A - Anticorps anti-tim-3 et compositions - Google Patents
Anticorps anti-tim-3 et compositionsInfo
- Publication number
- MA44659A MA44659A MA044659A MA44659A MA44659A MA 44659 A MA44659 A MA 44659A MA 044659 A MA044659 A MA 044659A MA 44659 A MA44659 A MA 44659A MA 44659 A MA44659 A MA 44659A
- Authority
- MA
- Morocco
- Prior art keywords
- tim
- antibodies
- compositions
- Prior art date
Links
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662321476P | 2016-04-12 | 2016-04-12 | |
| PCT/EP2017/058696 WO2017178493A1 (fr) | 2016-04-12 | 2017-04-11 | Anticorps anti-tim-3 et compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA44659A true MA44659A (fr) | 2021-04-14 |
| MA44659B1 MA44659B1 (fr) | 2021-12-31 |
Family
ID=58547516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA44659A MA44659B1 (fr) | 2016-04-12 | 2017-04-11 | Anticorps anti-tim-3 et compositions |
Country Status (34)
| Country | Link |
|---|---|
| US (2) | US11390674B2 (fr) |
| EP (2) | EP3978531A1 (fr) |
| JP (2) | JP7123804B2 (fr) |
| KR (1) | KR102473028B1 (fr) |
| CN (2) | CN116693685A (fr) |
| AU (1) | AU2017251250B2 (fr) |
| BR (1) | BR112018070919A2 (fr) |
| CA (1) | CA3020647A1 (fr) |
| CL (1) | CL2018002878A1 (fr) |
| CO (1) | CO2018010458A2 (fr) |
| CY (1) | CY1125440T1 (fr) |
| DK (1) | DK3443009T3 (fr) |
| EA (1) | EA039020B1 (fr) |
| ES (1) | ES2900381T3 (fr) |
| HR (1) | HRP20211820T1 (fr) |
| HU (1) | HUE056677T2 (fr) |
| IL (1) | IL262176B2 (fr) |
| LT (1) | LT3443009T (fr) |
| MA (1) | MA44659B1 (fr) |
| MD (1) | MD3443009T2 (fr) |
| MX (1) | MX2018012076A (fr) |
| PE (1) | PE20181805A1 (fr) |
| PH (1) | PH12018502112A1 (fr) |
| PL (1) | PL3443009T3 (fr) |
| PT (1) | PT3443009T (fr) |
| RS (1) | RS62736B1 (fr) |
| SA (1) | SA518400222B1 (fr) |
| SG (2) | SG10201912937SA (fr) |
| SI (1) | SI3443009T1 (fr) |
| TN (1) | TN2018000333A1 (fr) |
| TW (1) | TWI752950B (fr) |
| UA (1) | UA126854C2 (fr) |
| WO (1) | WO2017178493A1 (fr) |
| ZA (1) | ZA201806429B (fr) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3274370T (lt) | 2015-03-23 | 2020-02-10 | Bayer Pharma Aktiengesellschaft | Antikūnai prieš ceacam6 ir jų panaudojimas |
| JP7027401B2 (ja) | 2016-07-14 | 2022-03-01 | ブリストル－マイヤーズ スクイブ カンパニー | Ｔｉｍ３に対する抗体およびその使用 |
| JP2020513009A (ja) | 2017-04-05 | 2020-04-30 | シムフォゲン・アクティーゼルスカブＳｙｍｐｈｏｇｅｎ Ａ／Ｓ | Ｐｄ−１、ｔｉｍ−３、およびｌａｇ−３を標的とする併用治療 |
| IL310079A (en) | 2017-08-28 | 2024-03-01 | Bristol Myers Squibb Co | TIM-3 antagonists for the treatment and diagnosis of cancer |
| JP7358361B2 (ja) * | 2018-01-12 | 2023-10-10 | ブリストル－マイヤーズ スクイブ カンパニー | Ｔｉｍ３に対する抗体およびその使用 |
| WO2019179420A1 (fr) * | 2018-03-20 | 2019-09-26 | Wuxi Biologics (Shanghai) Co., Ltd. | Nouveaux anticorps anti-tim-3 |
| TW202003565A (zh) | 2018-03-23 | 2020-01-16 | 美商必治妥美雅史谷比公司 | 抗mica及/或micb抗體及其用途 |
| WO2019196911A1 (fr) * | 2018-04-12 | 2019-10-17 | Nanjing Leads Biolabs Co., Ltd. | Anticorps de liaison à tim-3 et son utilisation |
| EP3785732A4 (fr) | 2018-04-24 | 2022-02-23 | Ampsource Biopharma Shanghai Inc. | Anticorps dirigé contre tim-3 et application associée |
| CN112566936A (zh) * | 2018-08-21 | 2021-03-26 | 阿尔伯特爱因斯坦医学院 | 针对人tim-3的单克隆抗体 |
| CN111253485A (zh) * | 2018-11-30 | 2020-06-09 | 上海开拓者生物医药有限公司 | 抗人tim-3单克隆抗体及其应用 |
| KR20210104704A (ko) | 2018-12-19 | 2021-08-25 | 바이엘 악티엔게젤샤프트 | 항 ceacam6 및 tim3 항체의 제약 조합물 |
| KR20220016157A (ko) | 2019-05-30 | 2022-02-08 | 브리스톨-마이어스 스큅 컴퍼니 | 세포 국재화 시그너쳐 및 조합 요법 |
| WO2020243568A1 (fr) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Procédés d'identification d'un sujet approprié pour une thérapie d'immuno-oncologie (i-o) |
| US20220363760A1 (en) | 2019-05-30 | 2022-11-17 | Bristol-Myers Squibb Company | Multi-tumor gene signature for suitability to immuno-oncology therapy |
| KR102572804B1 (ko) * | 2020-02-25 | 2023-08-31 | 국립암센터 | CD11b+ 세포에서 TIM-3의 발현 수준을 측정하는 암 진단 또는 예후 예측을 위한 정보제공 방법 |
| CN113214396B (zh) * | 2020-07-31 | 2022-04-19 | 北京市神经外科研究所 | 抗tim3的单链抗体及其在制备治疗肿瘤的药物中的用途 |
| AU2021334361A1 (en) | 2020-08-31 | 2023-05-11 | Bristol-Myers Squibb Company | Cell localization signature and immunotherapy |
| WO2022120179A1 (fr) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Signatures géniques multi-tumorales et leurs utilisations |
| AU2021411486A1 (en) | 2020-12-28 | 2023-06-29 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
| JP2024501029A (ja) | 2020-12-28 | 2024-01-10 | ブリストル－マイヤーズ スクイブ カンパニー | Ｐｄ１／ｐｄ－ｌ１抗体の皮下投与 |
| EP4314068A1 (fr) | 2021-04-02 | 2024-02-07 | The Regents Of The University Of California | Anticorps dirigés contre un cdcp1 clivé et leurs utilisations |
| AR126001A1 (es) * | 2021-06-01 | 2023-08-30 | Symphogen As | Anticuerpos y composiciones anti-nkg2a |
| AU2022340907A1 (en) | 2021-09-02 | 2024-03-07 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Anti-cecam6 antibodies with reduced side-effects |
| AU2022336665A1 (en) | 2021-09-03 | 2024-03-21 | Oncoone Research & Development Gmbh | IMPROVED Fc SILENCED ANTI-oxMIF ANTIBODIES WITH REDUCED AGGREGATION POTENTIAL AND REDUCED HYDROPHOBICITY |
| WO2023178329A1 (fr) | 2022-03-18 | 2023-09-21 | Bristol-Myers Squibb Company | Procédés d'isolement de polypeptides |
| WO2023235847A1 (fr) | 2022-06-02 | 2023-12-07 | Bristol-Myers Squibb Company | Compositions d'anticorps et leurs procédés d'utilisation |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| WO1986005807A1 (fr) | 1985-04-01 | 1986-10-09 | Celltech Limited | Lignee cellulaire de myelomes transformee et procede d'expression d'un gene codant un polypeptide eucaryotque employant cette lignee |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
| US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| EP1105427A2 (fr) | 1998-08-17 | 2001-06-13 | Abgenix, Inc. | Production de molecules modifiees avec demi-vie serique prolongee |
| US6517529B1 (en) | 1999-11-24 | 2003-02-11 | Radius International Limited Partnership | Hemodialysis catheter |
| EP2252319A2 (fr) | 2008-01-29 | 2010-11-24 | The Brigham and Women's Hospital, Inc. | Procédés pour moduler une population de cellules myéloïdes suppressives et leurs utilisations |
| WO2010084999A1 (fr) | 2009-01-26 | 2010-07-29 | Protegene, Inc. | Agents immunosuppresseurs et agents prophylactiques et thérapeutiques pour des maladies auto-immunes |
| EP2417984B1 (fr) | 2009-04-10 | 2016-03-30 | Kyowa Hakko Kirin Co., Ltd. | Procédé pour le traitement d'une tumeur sanguine utilisant un anticorps anti-tim-3 |
| TR201807750T4 (tr) * | 2010-06-11 | 2018-06-21 | Kyowa Hakko Kirin Co Ltd | Anti-TIM-3 antikoru. |
| JP2013532153A (ja) | 2010-06-18 | 2013-08-15 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | 慢性免疫病に対する免疫治療のためのｔｉｍ−３およびｐｄ−１に対する二重特異性抗体 |
| WO2013006490A2 (fr) * | 2011-07-01 | 2013-01-10 | Cellerant Therapeutics, Inc. | Anticorps se liant spécifiquement à tim3 |
| EP3049442A4 (fr) | 2013-09-26 | 2017-06-28 | Costim Pharmaceuticals Inc. | Méthodes de traitement de cancers hématologiques |
| CN103936853B (zh) | 2014-01-26 | 2016-08-17 | 中国人民解放军军事医学科学院基础医学研究所 | 一种检测tim-3试剂盒及其使用方法 |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| JP6903432B2 (ja) | 2014-03-12 | 2021-07-14 | イエダ リサーチ アンド ディベロップメント カンパニー リミテッド | Ｃｎｓの疾患および傷害を処置するために全身性調節性ｔ細胞のレベルまたは活性を低下させること |
| CA2946606C (fr) | 2014-05-13 | 2023-06-06 | Bavarian Nordic A/S | Polytherapie pour le traitement du cancer a l'aide d'un poxvirus exprimant un antigene tumoral et un antagoniste de tim-3 |
| WO2016111947A2 (fr) | 2015-01-05 | 2016-07-14 | Jounce Therapeutics, Inc. | Anticorps inhibiteurs d'interactions de tim-3:lilrb2 et leurs utilisations |
| US9873741B2 (en) * | 2015-03-06 | 2018-01-23 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind TIM3 |
| EP3316902A1 (fr) | 2015-07-29 | 2018-05-09 | Novartis AG | Polythérapies comprenant des molécules d'anticorps contre tim -3 |
| US11014983B2 (en) | 2015-08-20 | 2021-05-25 | Sutro Biopharma, Inc. | Anti-Tim-3 antibodies, compositions comprising anti-Tim-3 antibodies and methods of making and using anti-Tim-3 antibodies |
| KR102146319B1 (ko) | 2015-10-02 | 2020-08-25 | 에프. 호프만-라 로슈 아게 | Pd1 및 tim3에 특이적인 이중특이성 항체 |
| JP7027401B2 (ja) | 2016-07-14 | 2022-03-01 | ブリストル－マイヤーズ スクイブ カンパニー | Ｔｉｍ３に対する抗体およびその使用 |
| JOP20190013A1 (ar) | 2016-08-25 | 2019-01-31 | Lilly Co Eli | أجسام مضادة لـ (تي آي ام -3) |
| JOP20190133A1 (ar) | 2016-12-08 | 2019-06-02 | Innovent Biologics Suzhou Co Ltd | أجسام مضادة لـ Tim-3 لمزجها بأجسام مضادة لـ PD-1 |
| JP2020513009A (ja) | 2017-04-05 | 2020-04-30 | シムフォゲン・アクティーゼルスカブＳｙｍｐｈｏｇｅｎ Ａ／Ｓ | Ｐｄ−１、ｔｉｍ−３、およびｌａｇ−３を標的とする併用治療 |
| JOP20190222A1 (ar) | 2017-04-11 | 2019-09-24 | Zymeworks Inc | الأجسام المضادة ثنائية النوعية المضادة لـ pd-l1 والمضادة لـ tim-3 |
-
2017
- 2017-04-11 EA EA201892294A patent/EA039020B1/ru unknown
- 2017-04-11 CA CA3020647A patent/CA3020647A1/fr active Pending
- 2017-04-11 AU AU2017251250A patent/AU2017251250B2/en active Active
- 2017-04-11 HU HUE17717393A patent/HUE056677T2/hu unknown
- 2017-04-11 MX MX2018012076A patent/MX2018012076A/es unknown
- 2017-04-11 RS RS20211517A patent/RS62736B1/sr unknown
- 2017-04-11 MA MA44659A patent/MA44659B1/fr unknown
- 2017-04-11 SG SG10201912937SA patent/SG10201912937SA/en unknown
- 2017-04-11 PE PE2018001979A patent/PE20181805A1/es unknown
- 2017-04-11 PL PL17717393T patent/PL3443009T3/pl unknown
- 2017-04-11 MD MDE20190216T patent/MD3443009T2/ro unknown
- 2017-04-11 TW TW106112034A patent/TWI752950B/zh active
- 2017-04-11 SG SG11201808724SA patent/SG11201808724SA/en unknown
- 2017-04-11 HR HRP20211820TT patent/HRP20211820T1/hr unknown
- 2017-04-11 EP EP21194637.1A patent/EP3978531A1/fr active Pending
- 2017-04-11 TN TNP/2018/000333A patent/TN2018000333A1/en unknown
- 2017-04-11 CN CN202310660864.5A patent/CN116693685A/zh active Pending
- 2017-04-11 ES ES17717393T patent/ES2900381T3/es active Active
- 2017-04-11 EP EP17717393.7A patent/EP3443009B1/fr active Active
- 2017-04-11 US US16/093,024 patent/US11390674B2/en active Active
- 2017-04-11 LT LTEPPCT/EP2017/058696T patent/LT3443009T/lt unknown
- 2017-04-11 JP JP2018553410A patent/JP7123804B2/ja active Active
- 2017-04-11 UA UAA201811058A patent/UA126854C2/uk unknown
- 2017-04-11 WO PCT/EP2017/058696 patent/WO2017178493A1/fr active Application Filing
- 2017-04-11 IL IL262176A patent/IL262176B2/en unknown
- 2017-04-11 DK DK17717393.7T patent/DK3443009T3/da active
- 2017-04-11 BR BR112018070919A patent/BR112018070919A2/pt unknown
- 2017-04-11 PT PT177173937T patent/PT3443009T/pt unknown
- 2017-04-11 SI SI201731008T patent/SI3443009T1/sl unknown
- 2017-04-11 KR KR1020187032586A patent/KR102473028B1/ko active IP Right Grant
- 2017-04-11 CN CN201780023412.9A patent/CN109451741B/zh active Active
-
2018
- 2018-09-27 ZA ZA2018/06429A patent/ZA201806429B/en unknown
- 2018-09-28 CO CONC2018/0010458A patent/CO2018010458A2/es unknown
- 2018-10-01 PH PH12018502112A patent/PH12018502112A1/en unknown
- 2018-10-09 CL CL2018002878A patent/CL2018002878A1/es unknown
- 2018-10-11 SA SA518400222A patent/SA518400222B1/ar unknown
-
2021
- 2021-12-08 CY CY20211101076T patent/CY1125440T1/el unknown
-
2022
- 2022-05-11 US US17/741,967 patent/US20230105714A1/en active Pending
- 2022-08-10 JP JP2022128330A patent/JP2022172142A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA46525A (fr) | Anticorps anti-lag-3 et compositions | |
| MA44659A (fr) | Anticorps anti-tim-3 et compositions | |
| MA47694A (fr) | Anticorps anti-tigit | |
| MA49034A (fr) | Anticorps anti-lag3 | |
| FR21C1030I2 (fr) | Conjugué anticorps anti-her2-médicament | |
| MA47268A (fr) | Anticorps anti-gpc3 | |
| KR102162129B9 (ko) | 항-갈렉틴-9 항체 및 이의 용도 | |
| MA45004A (fr) | Anticorps spécifiques anti-wt1-hla | |
| MA46041A (fr) | Anticorps anti-tim -3 | |
| DK3368572T3 (da) | Anti-pd-1-antistoffer og -sammensætninger | |
| MA46057A (fr) | Anticorps anti-ctla4 | |
| MA53434A (fr) | Anticorps anti-tigit | |
| MA49537A (fr) | Anticorps anti-lag3 et leurs utilisations | |
| KR20180084817A (ko) | 항-siglec-9 항체 및 이의 이용 방법 | |
| MA52884A (fr) | Anticorps anti-il-11 | |
| MA47472A (fr) | Anticorps | |
| MA49726A (fr) | Formulation d'anticorps anti-cgrp | |
| MA46272A (fr) | Anticorps anti-cd27 | |
| MA45125A (fr) | Anticorps anti-alpha-synucléine et leurs utilisations | |
| MA45231A (fr) | Anticorps anti-ige | |
| MA50352A (fr) | Anticorps multispécifiques | |
| DK3316909T3 (da) | Anti-ntb-a-antistoffer og relaterede sammensætninger og fremgangsmåder | |
| MA49749A (fr) | Anticorps anti-cd137 | |
| MA45233A (fr) | Anticorps anti-gitr et leurs utilisations | |
| MA45543A (fr) | Anticorps anti-peptides n3pglu amyloïdes bêta et utilisations associées |